What is the Fiscal Year for Sol-Gel Technologies?
Date: November 13, 2026
Sol-Gel Technologies's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q2, which ends on June 30, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q2
Current Quarter End
June 30, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Ness Ziona, Israel
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
SLGL
Website
https://sol-gel.comDescription
Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our unique technology platform was designed to enable drug substances to be entrapped in porous silica microcapsules in order to address the limitations of topical drug delivery by stabilizing active drug ingredients, extending drug delivery time and reducing potential irritation caused by direct application to the skin. For more information, please visit www.Sol-Gel.com
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Sol-Gel Technologies and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.